Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 177Lu-DOTA-ABM-5G |
| Synonyms | |
| Therapy Description |
177Lu-DOTA-ABM-5G is a radioconjugate comprising a peptide targeting ITGB6 (integrin alphaVbeta6) linked to the radionuclide Lutetium-177, which potentially inhibits tumor growth (PMID: 36207137). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 177Lu-DOTA-ABM-5G | [177Lu] DOTA-ABM-5G | 177Lu-DOTA-ABM-5G is a radioconjugate comprising a peptide targeting ITGB6 (integrin alphaVbeta6) linked to the radionuclide Lutetium-177, which potentially inhibits tumor growth (PMID: 36207137). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06389123 | Phase I | 177Lu-DOTA-ABM-5G | Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas | Recruiting | USA | 0 |
| NCT06228482 | Phase I | 177Lu-DOTA-ABM-5G | Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6 | Recruiting | USA | 0 |